Research offers clues to Parkinson’s disease causes and potential drug target

13th August, 2015

A stage-by-stage picture of a key cellular mechanism associated with the development of Parkinson’s Disease has been captured for the first time by a research team led by the University of Dundee.

The findings give further understanding of the possible causes of Parkinson’s disease and offer potential for multiple targets for therapeutics to be developed.

Parkinson’s disease (PD) is a neurodegenerative disorder with severe motor and non-motor symptoms. There are several genes associated with PD, with autosomal recessive juvenile Parkinsonism (ARJP) being the most prevalent inherited form of the disease.

It is recognised that mutations in the PARK2 gene leads to ARJP, with PARK2 mutations causing more than 50 per cent of cases. This gene makes a protein called parkin.

Researchers led by Dr Helen Walden at the University of Dundee, and involving collaborators from the University of Western Ontario, have uncovered a series of stages showing how that activation occurs.

“Parkin is a protein which exists in what we call an auto-inhibited state,” said Dr Walden. “What we have done is work out how Parkin is kept switched off, and how it is switched on. It is necessary for it to be switched off because it is only needed under certain conditions.

“One part of the protein keeps it switched off. Effectively there is a 'safety catch’ on the surface of the protein but it is hidden. When the activation process starts, the protein is modified and removes the cover for the safety catch. Once the safety catch is pressed, the inhibiting module is ejected, leaving the way clear for parkin to interact with the factors needed to do its job.

“By defining the multiple steps needed for going from off to on, we have provided the information needed to modulate each step. This is important because it reveals the mechanics behind a process that goes wrong in so many cases of Parkinson’s Disease.

“The fact there are several different stages offers the possibility of different ways to tackle the problems that occur in mutations of the gene and the subsequent activation, or lack of it, of parkin.”

The results of the research have been published in The EMBO Journal.

Dr Walden is a Programme Leader in the MRC Protein Phosphorylation and Ubiquitylation Unit (MRC PPU) at The University of Dundee. Her work has been focused on understanding the intricate molecular architecture of proteins.

University of Dundee News

<< Back to Announcements